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Background: The prognosis of patients with metastatic melanomas is extremely heterogeneous. Therefore,
identifying high-risk subgroups by using innovative prediction models would help to improve selection of
appropriate management options.
Methods: In this study, two datasets (GSE7929 and GSE7956) of mRNA expression microarray in an animal melanoma
model were normalized by frozen Robust Multi-Array Analysis and then combined by the distance-weighted
discrimination method to identify time course-dependent metastasis-related gene signatures by Biometric
Research Branch-ArrayTools (BRB)-ArrayTools. Then two datasets (GSE8401 and GSE19234) of clinical melanoma
samples with relevant clinical and survival data were used to validate the prognosis signature.
Results: A novel 192-gene set that varies significantly in parallel with the increasing of metastatic potentials
was identified in the animal melanoma model. Further, this gene signature was validated to correlate with
poor prognosis of human metastatic melanomas but not of primary melanomas in two independent datasets.
Furthermore, multivariate Cox proportional hazards regression analyses demonstrated that the prognostic value
of the 192-gene set is independent of the TNM stage and has higher areas under the receiver operating
characteristic curve than stage information in both validation datasets.
Conclusion: Our findings suggest that a time course-dependent metastasis-related gene expression signature is
useful in predicting survival of malignant melanomas and might be useful in informing treatment decisions for
these patients.
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The incidence of malignant melanoma, an aggressive
form of skin cancer, is increasing rapidly globally, includ-
ing in China [1]. It has been estimated that approxi-
mately 15% of patients with primary melanoma will
develop distant metastases [2]. Because metastatic mel-
anoma responds poorly to conventional therapy, its out-
come is generally very poor [3,4]. However, a proportion
of patients do survive for prolonged periods following
development of metastasis. Therefore, developing in-
novative prediction models for stratifying metastatic* Correspondence: rongyichengy@163.com; linjiaxi22@126.com
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unless otherwise stated.melanoma further would improve planning of appropri-
ate managements.
Gene expression profiling has been used to establish
molecular signatures for classifying the subtypes of pri-
mary tumors and predicting the clinical outcome of
multiple cancers including malignant melanoma [5,6].
Previous studies have identified several panels of gene
expression signatures with clinical relevance to malig-
nant melanoma. In this study, we identified a novel gene
signature based on time course mRNA expression
microarray data in an animal melanoma model that can
be used to predict survival in patients with malignant
melanomas.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Datasets
The gene expression profiles of four independent data-
sets deposited in the Gene Expression Omnibus (GEO)
(accession numbers GSE7929, GSE7956, GSE8401, and
GSE19234) were analyzed [7,8]. Microarray platforms used
in these datasets were HU133A Affymetrix DNA chips
(GSE7929, GSE7956, GSE8401) and Illumina HumanWG-6
v2 E/HumanWG HT12 Expression Beadchip (GSE19234).
The GSE7929 comprises the gene expression microarray
data of 32 human melanoma cells samples including 11
replicas of parental melanoma cell line A375 (LeiATCC)
and 21 derived cell lines with different metastatic potentials
selected based on a xenotransplant metastasis model [7].
The GSE7956 dataset comprises whole-genome mRNA
expression data of 39 human melanoma cell samples, in-
cluding 10 replicas of parental melanoma cell line A375
(LeiFidler) and 29 derived cell lines with different meta-
static potentials generated by two or three rounds of selec-
tion in immunodeficient mice [7].
The GSE8401 dataset was generated from 83 melanoma
samples (31 primary and 52 metastatic tumors) that were
collected from patients undergoing surgery were collected
from 1992 to 2001 at the Massachusetts General Hospital
and Harvard Medical School as a part of the diagnostic
workup or planning of therapy [7]. Fifty-two of these
metastatic melanoma samples were of superficially spread-
ing type, 19 nodular, and 5 acral lentiginous; the types areFigure 1 A Box-plot of gene expression in each metastatic melanoma
Using distance-weighted discrimination (DWD) method after frozen Robust
effect removal.not available for the remaining. Most of the primary mela-
nomas were TNM stage I-II, the metastatic melanoma
group includes 17 stage III and 35 stage IV tumors [7].
The GSE19234 dataset comprises 44 melanoma tu-
mors with metastasis were collected at the New York
University Medical Center from 1988 to 1997 [8]. Five
cases received immunotherapy. Fifteen cases showed
CD3 positive. Among these tumors, 4 cases were at
stage IIIA tumors,23 at stage IIIB, 12 at stage IIIC, and 5
at stage IV [8].
As claimed in the original publications, all the studies
on these datasets had been approved by the local ethical
committees and samples were collected with written in-
formed consent from the patients.
Microarray data merging
Two human melanoma cell line datasets GSE7929
and GSE7956 were used to identifying time course-
dependent metastasis-related gene signatures. All gene
expression profiles were normalized with frozen Robust
Multi-Array Analysis (fRMA), a procedure in which al-
lows arrays are not longer clustered per study but per
platform [9]. The two datasets were combined using the
distance-weighted discrimination (DWD) method [10].
DWD is a multivariate analysis tool that is able to adjust
experiments batch effects to compensate for biases
present in different gene expression datasets. The inte-
gration effect was inspected by a box-plot of genearray of the combined dataset (GSE7929 and GSE7956).
Multi-Array Analysis (fRMA) normalization indicates a good batch
Figure 2 Hierarchical clustering of samples of the combined datasets (GSE7929 and GSE7956) by the time course gene set. Parental
lines samples were assigned as “time course 0”; metastatic derived cell lines established after one round of selection as “time course 1” (n = 24);
derived cell lines after two or three rounds of selection as “time course 2”.
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Branch (BRB)-ArrayTools 4.3.1 [11].
Time course analysis of metastasis-related gene signature
on merged dataset
A time course analysis of the combined datasets of
GSE7929 and GSE7956 was performed with the expression
profiles of different generations of metastatic cell lines set
as time-course data. A BRB-ArrayTool plug-in was used to
perform regression analysis of time course expression data
to identify the genes whose expression varies over time.Figure 3 Survival prediction using a 192-gene signature in two valida
significantly shorter overall survival time than low-risk group in GSE8401 (A
not in primary tumor subgroup of GSE8401 (D). (By Kaplan-Meier curve meThe round numbers of different generations of selected
cells were set as different time points. The tests were per-
formed at a false discovery rate (FDR) threshold of 0.05. A
list of genes that satisfied this threshold was produced and
used as gene sets to assess correlations with poor survival
of patients with melanomas in the validation datasets.
Validation of the time course prediction gene signature in
independent datasets
Two clinical melanoma sample datasets (GSE8401 and
GSE19234) were used to validate the prognostiction datasets. High-risk group defined by a 192 gene set had a
), GSE19234 (B), and metastatic tumor subgroup of GSE8401 (C), but
thod and log-rank statistics based on 100 permutations).
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related gene signature. For the validated datasets, series
matrix files containing normalized data were obtained from
the GEO. Survival risk prediction of the gene expression
data by the time course-dependent metastatic gene signa-
ture was performed based on principal components with
BRB-ArrayTools software. Survival risk prediction was
based on 10-fold cross-validation and classified patients
into low- and high-risk groups according to the prognostic
indexes.
Statistics
Distributions of overall survival were assessed using the
Kaplan-Meier curve method and log-rank statistics based
on 100 permutations. Multivariate analyses of prognostic
factors were based on the Cox proportional hazards model.
Area under the receiver operating characteristic (ROC)
curves were used as a performance measure for prognostic
factors. Permutated Kaplan-Meier curve analysis was per-
formed using BRB-ArrayTools. All other statistical analyses
were performed with Medcalc Software. P values less than
0.05 were considered statistically significant.
Results
In this study, a gene set that correlated with the meta-
static potential of melanoma cell lines was first identified
from the gene expression profiling of two datasets
(GSE7929 and GSE7956). To increase power, these two
data sets were merged by the DWD method after fRMA
normalization. As seen in Figure 1, after merging, the
relative log gene expression plots indicated a good batch
effect removal.
The merged dataset comprised of 71 samples among
which the parental lines samples were assigned as “time
course 0” (n = 21); metastasis-derived cell lines established
after one round of selection as “time course 1” (n = 24);
derived cell lines after two or three rounds of selection as
“time course 2” (n = 26). Cells at different metastatic
stages had distinct expression patterns. As seen in Figure 2
and in the Additional file 1, 192 genes were identified byFigure 4 Comparison of ROC curves between 192-gene set signature
with higher areas under the ROC curve than those with stage information
B: GSE19234).BRB-ArrayTools as changing significantly over the time
course with an FDR threshold of 0.05. Furthermore, this
192-gene signature was compared with a previously iden-
tified 150-gene signature in GSE8401 and 266-gene signa-
ture in GSE19234. There was little gene overlap among
these three gene sets, which indicates that our 192-gene
signature is novel for predicting survival of patients with
metastatic melanoma.
Next, the robustness with which the 192 metastasis-
related gene expression signature in predicts survival in
patients with melanomas was further tested with whole-
genome mRNA expression profiling data obtained from
two completely independent datasets (GSE8401 and
GSE19234). Using the prognostic indexes based on our
gene signature, patients were partitioned into high- and
low-risk groups. As seen in Figure 3 the high-risk groups
was observed to have a significantly shorter overall sur-
vival time than the low-risk group in 55 metastatic mela-
nomas of GSE8401, and 44 metastatic melanomas of
GSE19234. However, no significant difference in survival
between high- and low-risk groups was observed for pri-
mary melanoma samples of GSE8401 Figure 4.
Multivariate Cox proportional hazards regression ana-
lyses showed that the prognostic value of our 192-gene
signature was independent of TNM stage in both valid-
ation datasets (Table 1). The Cox model with the 192-
gene signature was also found to provide a predictive
performance with higher areas under the ROC curve
than TNM stage.
Discussion
Because metastatic melanomas are heterogeneous, it is
critical to develop reliable clinical or molecular predic-
tors to identify those with a relatively worse prognosis
and thus select those that could benefit from more
aggressive therapies. Previous studies have identified
two survival-related gene signatures for patients with
metastatic melanoma. The first signature, a 266-gene
signature, was generated using the Significant Analysis
of Microarrays (SAM) method and could enhanceand TNM stage. A 192-gene signature gave a predictive performance
in both two validation datasets of metastatic melanoma (A: GSE840;
Table 1 Multivariate Cox proportional hazards regression
analyses on survival time in two metastatic melanoma
datasets
Covariate P Exp(b) 95% CI of Exp (b)
GSE8401
192-gene signature 0.0043 2.8517 1.3948 to 5.8301
Stage 0.0585 2.1791 0.9764 to 4.8633
GSE19234
192-gene signature 0.0353 2.7182 1.0762 to 6.8655
Stage 0.0172 1.9844 1.1323 to 3.4778
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clinical staging [8]. A more earlier study by Xu et al. [7]
compared the gene expression patterns of highly meta-
static human melanoma cell lines derived from poorly
metastatic parental lines in an animal metastasis model
using the Gene Set Enrichment Analysis (GSEA) method
and thus identified another survival-related 150-gene set
for predicting prognosis of metastatic melanomas.
In this study, we re-analyzed the same dataset of ani-
mal melanoma models as that assessed by Xu et al. [7].
Unlike the original study, we used a time-course strategy
to isolate metastasis-related genes. We identified 192
genes that varied significantly in parallel with increasing
metastatic potential; this set differs from the previously
identified gene sets. We confirmed that this time-course
gene expression changes in an animal melanoma model
correlate with survival of patients with melanoma metas-
tases in two independent datasets. Moreover, our novel
time-course gene signature predictor is independent of
stage, and has better predictive performance than stage.
Our findings suggest that this 192-gene signature might
improve the ability of TNM staging to predict survival
of patients with metastatic melanoma. Further, we also
found that gene expression signatures from animal mel-
anoma model and human melanoma datasets could be
reconciled.
Interpretation of gene function showed that the 192
genes are enriched significantly in extracellular matrix re-
ceptor interaction, focal adhesion and the β-transforming
growth factor signaling pathway. Many of these genes
have previously been implicated in melanoma metastasis
and prognosis prediction, including MYC, GPNMB,
GAB2, and SATB1 [12-15]. Therefore, the functional sig-
nificance of this 192-gene pathway also warrants further
investigation.Conclusions
In conclusion, the time course-dependent gene signature
we have developed is useful for predicting survival of pa-
tients with metastatic melanomas and might be useful
for informing treatment decisions.Additional file
Additional file 1: A 192-gene set that varies significantly in parallel
with the increasing of metastatic potentials of melanoma.
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